| __timestamp | Bio-Techne Corporation | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 20622000 |
| Thursday, January 1, 2015 | 119401000 | 33837000 |
| Friday, January 1, 2016 | 140879000 | 35979000 |
| Sunday, January 1, 2017 | 199243000 | 25003000 |
| Monday, January 1, 2018 | 240636000 | 19269000 |
| Tuesday, January 1, 2019 | 264359000 | 15426000 |
| Wednesday, January 1, 2020 | 260583000 | 14456000 |
| Friday, January 1, 2021 | 324951000 | 20488000 |
| Saturday, January 1, 2022 | 372766000 | 27195000 |
| Sunday, January 1, 2023 | 378378000 | 30914000 |
| Monday, January 1, 2024 | 396826000 |
Data in motion
In the dynamic world of biotechnology, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial for evaluating company performance. Over the past decade, Bio-Techne Corporation has demonstrated a robust growth trajectory in SG&A expenses, increasing by over 550% from 2014 to 2023. This reflects their strategic investments in expanding operations and market reach. In contrast, Celldex Therapeutics, Inc. has shown a more conservative approach, with a modest 50% increase in SG&A expenses over the same period. This disparity highlights differing strategic priorities, with Bio-Techne focusing on aggressive expansion, while Celldex maintains a leaner operational model. Notably, data for Celldex in 2024 is unavailable, suggesting potential shifts in reporting or operational strategy. This analysis underscores the importance of SG&A efficiency as a key indicator of a biotech company's strategic direction and market positioning.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Who Optimizes SG&A Costs Better? AbbVie Inc. or Celldex Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
Bio-Techne Corporation or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Xencor, Inc.
Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Axsome Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Celldex Therapeutics, Inc. vs Xencor, Inc. Trends and Insights